Skip to main content
SpringerLink
Log in

Perfluorocarbons as Blood Substitutes: Limitation of Complement Activation in the Control of Adverse Reactions

  • Conference paper
6th International Symposium on Intensive Care and Emergency Medicine

Part of the book series: Update in Intensive Care and Emergency Medicine ((UICM,volume 1))

Abstract

Blood is ordinarily the best substitute for blood. However, there exists a variety of circumstances in which the use of blood may be impractical, or in which blood’s rheologic or immunologic properties are suboptimal. A number of examples may readily be cited: Trauma or other hemorrhage occurring at a location distant from transfusion facilities; Presence of a rare blood type, making it difficult to locate suitable blood; Presence of immune hemolysis or isoimmunization, making proper cross-matching difficult; Ex-vivo organ preservation; Underperfused, radio-and-chemoresistant tumors; Refusal of transfusion on religious grounds. Each of these circumstances could be a context in which an oxygen-carrying blood substitute could be of use, especially if it had a long shelf life under simple storage conditions and was a true solution or an emulsion with a particle size smaller than that of erythrocytes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Birndorff NI, Lopas HJ (1970) Effects of red cell stroma-free hemoglobin solution on renal function in monkeys. J Appl Physiol 29: 573–578

    Google Scholar 

  2. Cochin A, DasGupta TK, De Woskin R et al (1972) Immunogenic properties of stroma vs stroma-free hemoglobin solution (Amer Coll Surg) Surg Forum 23: 19–21

    CAS  Google Scholar 

  3. Benesch RE, Yung S, Suzuki T, Bauer C, Benesch R (1973) Pyridoxal compounds as specific reagents for the alpha and beta N-terminal of hemoglobin. Proc Natl Acad Sci (USA) 70: 2595–2599

    Article  CAS  Google Scholar 

  4. Benesch RE, Benesch R, Renthal RD, Maeda N (1972) Affinity labeling of the polyphosphate binding site of hemoglobin. Biochem 11: 3576–3582

    Article  CAS  Google Scholar 

  5. Saunders S, Hedlund BE (1984) Electrostatic modification of protein surfaces: effect on hemoglobin ligation and solubility. Biochem 23: 1457–1461

    Article  CAS  Google Scholar 

  6. Didonato A, Fantl W, Acharya AS, Manning JM (1983) Selective carboxymethylation of the alpha-amino groups of hemoglobin: effect on functional properties J Biol Chem 258: 11890–11895

    CAS  Google Scholar 

  7. Bunn HF, Esham WT, Bull RW (1969) The renal handling of hemoglobin. I. Glomerular filtration. J Exp Med 129: 909–924

    Google Scholar 

  8. Clark L (Jr), Gollan F (1966) Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 152: 1755–1757

    Article  Google Scholar 

  9. Geyer RP ( 1973 Fluorocarbon-polyol artifical blood substitutes. N Engl J Med 289: 10771082

    Google Scholar 

  10. Geyer RP (1970) Whole animal perfusion with fluorocarbon suspensions. Fed Proc. 29: 1758–1763

    PubMed  CAS  Google Scholar 

  11. Ohyanagi H, Toshima K, Sekita M, Okamoto M, Ithoh T, Mitsuno T (1979) Clinical studies of perfluorochemical whole blood substitutes: safety of Fluosol-DA (20%) in normal human colunteers. Clin Ther 2: 306–312

    Google Scholar 

  12. Honda K, Hoshino S, Shoji M et al (1980) Clinical use of a blood substitute. N Engl J Med 303: 391–392

    Article  PubMed  CAS  Google Scholar 

  13. Mitsuno T, Harumasa O, Naito R (1982) Clinical studies of a perfluorochemical whole blood substitute ( Fluosol-DA ). Ann Surg 195: 60–69

    Google Scholar 

  14. Vercellotti GM, Hammerschmidt DE, Craddock PR, Jacob HS (1982) Activation of plasma complement by perfluorocarbon artifical blood: probable mechanism of adverse reactions in treated patients and rationale for corticosteroid prophylaxis. Blood 59: 1299–1304

    PubMed  CAS  Google Scholar 

  15. Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS (1977) Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis N Engl J Med 296: 769–774

    CAS  Google Scholar 

  16. Craddock PR, Fehr J, Dalmasso AP, Brigham KL, Jacob HS (1977) Hemodialysis neutropenia: pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 59: 879–888

    Article  PubMed  CAS  Google Scholar 

  17. O’Flaherty JT, Craddock PR, Jacob HS (1977) Mechanism of anticomplementary activity of corticosteroids in vivo: possible relevance to endotoxin shock. Proc Soc Exp Biol Med 154: 206–209

    PubMed  Google Scholar 

  18. Hammererschmidt DE, White JG, Craddock PR, Jacob HS (1979) Corticosteroids inhibit complement-mediated granulocyte aggregation: a possible mechanism for their efficacy in shock states. J Clin Invest 63: 798–803

    Article  Google Scholar 

  19. Hammerschmidt DE, Harris PD, Wayland JH, Craddock PR, Jacob HS (1981) Complement-induced granulocyte aggregation in vivo. Am J Pathol 102: 146–150

    PubMed  CAS  Google Scholar 

  20. Tremper KK, Friedman AE, Levine EM, Lapin R, Camarillo D (1982) The preoperative treatment of severely anemic patients with a perfluorochemical oxygen transfort fluid, Fluosol-DA. N Engl J Med 307: 277–283

    Google Scholar 

  21. Police AM, Waxman K, Tominage G (1985) Pulmonary complications after Fluosol administration to patients with life-threatening blood loss. Crit Care Med 13: 96–98

    Article  PubMed  CAS  Google Scholar 

  22. Kam KE, Ogburn PL, Julian T, Cerra FB, Hammerschmidt DE, Vercellotti GM (1985) Use of a whole blood substitute, Fluosol-DA 20%, after massive postpartum hemorrhage. Obstet Gynecol 65: 127–130

    Google Scholar 

  23. Dyerberg J, Bang HO (1979) Lipid metabolism, atherogenesis and haemostasis in Eskimos: the role of the prostaglandin-3 family. Haemostasis 8: 227–233

    PubMed  CAS  Google Scholar 

  24. Hammerschmidt DE, Ogburn PL, Williams JE (1984) Amniotic fluid activates complement: a role in amniotic fluid embolism syndrome? J Lab Clin Med 104: 901–907

    PubMed  CAS  Google Scholar 

  25. Hakim RM, Breillatt J, Lazarus JM, Port FK (1984) Complement activation and hypersensitivity reactions to dialysis membranes. N Engl. J Med 311: 878–882

    Google Scholar 

  26. Gewurz H, Mold C, Siegel J, Friedel B (1982) C-reactive protein and the acute phase response. Adv Intern Med 27: 345–372

    PubMed  CAS  Google Scholar 

  27. Vercellotti GM, Hammerschmidt DE (1985) Immunological biocompathibility in blood substitutes. Internat Anesth Clin 23: 47–62

    Article  CAS  Google Scholar 

  28. Ohyamali H, Mitsumo T (1975) Biophysiologic effects of perfluorochemicals as artificial blood. Proc Xth Internat Cong Nutr: Symposium on perfluorochemical artificial blood, Kyoto, pp 21–54

    Google Scholar 

  29. Geyer RP (1975) (ed): Symposium on artificial blood. Fed Proc 34:1428ß1431

    Google Scholar 

  30. Rosenblum WI, Hadfield MG, Martinez AJ, Schatzki P (1976) Alterations of liver and spleen following intravenous infusions of fluorocarbon emulsions. Arch Pathol Lab Med 100: 213–217

    PubMed  CAS  Google Scholar 

  31. Ohnishi Y, Kitzawa M (1980) Application of perfluorochemicals in human beings–a morphological report of a human autopsy case with some experimental studies using rabbits. Acta Pathol Jpn 30: 489–504

    PubMed  CAS  Google Scholar 

  32. Lutz J, Metzenauer P (1980) Effects of potential blood substitutes (perfluorochemicals) on rat liver and spleen. Pflügers Archiv 387: 175–181

    Article  PubMed  CAS  Google Scholar 

  33. Virmani R, Warren D, Rees R, Fink LM, English D (1983) Effects of perfluorochemical on phagocytic function of leukocytes. Transfusion 23: 512–515

    Article  PubMed  CAS  Google Scholar 

  34. Hammerschmidt DE (1986) Clinical utility of assays for complement anaphylatoxins, Complement (in press)

    Google Scholar 

  35. Craddock PR, Hammerschmidt DE, Whithe JG, Dalmasso, AP, Jacob HS (1977) Complement (C5a)-induced granulocyte aggregation in vitro: a possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest 60: 261–264

    Article  Google Scholar 

  36. Hammerschmidt DE, Bowers TK, Lammi-Keefe CJ, Jacob HS, Craddock PR (1980) Granulocyte aggregometry: a sensitive technique for the detection of C5a and complement activation. Blood 55: 898–902

    PubMed  CAS  Google Scholar 

  37. Hammerschmidt DE, Weaver LJ, Hudson LD, Craddock PR, Jacob HS (1980) Association of complement activation and elevation of plasma-05a with adult respiratory distress syndrome: pathophysiologic relevance and possible prognostic value. Lancet 1: 947–949

    Article  PubMed  CAS  Google Scholar 

  38. Hugli TE, Chenoweth DE (1980) Biologically active peptides of complement: techniques and significance of C3a and C5a measurements. In: Nakamura RM, Dito WR, Tucker ES [III] (eds) Immunoassays: Clinical Laboratory Technique for the 1980s Liss, Inc, New York, pp 443–460

    Google Scholar 

  39. Chenoweth DE (1984) Biocompatibility of hemodialysis membranes: evaluation with C3a anaphylatoxin radioimmunoassays. ASAIO J 7: 44–49

    CAS  Google Scholar 

  40. Chenoweth DE, Cheung AK, Henderson LW (1983) Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes. Kidney Intern 24: 764–769

    Article  CAS  Google Scholar 

  41. Ivanovich P, Chenoweth DE, Schmidt R, Klinkmann H, Boxer LA, Jacob HS, Hammerschmidt DE (1983) Symptoms and activation of granulocytes and complement with two dialysis membranes. Kidney Intern 24: 758–763

    Article  CAS  Google Scholar 

Download references

Authors
  1. D. E. Hammerschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. M. Vercellotti
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Intensive Care, Erasme Hospital, Free University of Brussels, Route de Lennik 808, B-1070, Brussels, Belgium

    J. L. Vincent

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Hammerschmidt, D.E., Vercellotti, G.M. (1986). Perfluorocarbons as Blood Substitutes: Limitation of Complement Activation in the Control of Adverse Reactions. In: Vincent, J.L. (eds) 6th International Symposium on Intensive Care and Emergency Medicine. Update in Intensive Care and Emergency Medicine, vol 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82801-0_52

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-82801-0_52

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-16508-8

  • Online ISBN: 978-3-642-82801-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation